305 related articles for article (PubMed ID: 27881009)
1. Late cardiac effect of anthracycline therapy in physically active breast cancer survivors - a prospective study.
Nagy AC; GulAcsi-BArdos P; CserEp Z; Hangody L; Forster T
Neoplasma; 2017; 64(1):92-100. PubMed ID: 27881009
[TBL] [Abstract][Full Text] [Related]
2. New insight into the intraventricular pressure gradient as a sensitive indicator of diastolic cardiac dysfunction in patients with childhood cancer after anthracycline therapy.
Shigemitsu S; Takahashi K; Yazaki K; Kobayashi M; Yamada M; Akimoto K; Tamaichi H; Fujimura J; Saito M; Nii M; Itatani K; Shimizu T
Heart Vessels; 2019 Jun; 34(6):992-1001. PubMed ID: 30673819
[TBL] [Abstract][Full Text] [Related]
3. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
Nagy AC; Tolnay E; Nagykálnai T; Forster T
Neoplasma; 2006; 53(6):511-7. PubMed ID: 17167721
[TBL] [Abstract][Full Text] [Related]
5. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study.
Nagy AC; Cserép Z; Tolnay E; Nagykálnai T; Forster T
Pathol Oncol Res; 2008 Mar; 14(1):69-77. PubMed ID: 18347931
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
7. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
8. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
9. Assessment of left ventricular systolic dysfunction by tissue Doppler imaging to detect subclinical cardiomyopathy early after anthracycline therapy.
Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Loperfido F; Biondi-Zoccai G
Minerva Cardioangiol; 2007 Dec; 55(6):711-20. PubMed ID: 18091640
[TBL] [Abstract][Full Text] [Related]
10. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
[No Abstract] [Full Text] [Related]
11. Tissue Doppler imaging adds incremental value in predicting exercise capacity in patients with congestive heart failure.
Terzi S; Sayar N; Bilsel T; Enc Y; Yildirim A; Ciloğlu F; Yesilcimen K
Heart Vessels; 2007 Jul; 22(4):237-44. PubMed ID: 17653517
[TBL] [Abstract][Full Text] [Related]
12. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study.
Mohamed AL; El-Abd AA; Mohamed HG; Noufal AM; Hennawy BS
Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102130. PubMed ID: 37858847
[TBL] [Abstract][Full Text] [Related]
13. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
14. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic Wave Velocity Propagation: A Novel Parameter for Assessing the Effect of Anthracycline Chemotherapy Agents on Cardiac Diastolic Function in Breast Cancer Patients.
Huang X; Fan XY; Cheng Q; Zhang J; Sun J; Tang QY; Deng YB; Bi XJ
Curr Med Sci; 2023 Dec; 43(6):1229-1237. PubMed ID: 38041790
[TBL] [Abstract][Full Text] [Related]
16. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.
Leger K; Slone T; Lemler M; Leonard D; Cochran C; Bowman WP; Bashore L; Winick N
Pediatr Blood Cancer; 2015 Jan; 62(1):123-7. PubMed ID: 25176022
[TBL] [Abstract][Full Text] [Related]
17. Rational and design of SATRACD study: detecting subclinical anthracycline therapy related cardiac dysfunction in low income country.
Zhang W; Azibani F; Okello E; Kayima J; Walusansa V; Orem J; Sliwa K
Afr Health Sci; 2021 Jun; 21(2):647-654. PubMed ID: 34795719
[TBL] [Abstract][Full Text] [Related]
18. Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
Koelwyn GJ; Lewis NC; Ellard SL; Jones LW; Gelinas JC; Rolf JD; Melzer B; Thomas SM; Douglas PS; Khouri MG; Eves ND
Oncologist; 2016 Feb; 21(2):141-9. PubMed ID: 26764251
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial.
Negishi T; Thavendiranathan P; Penicka M; Lemieux J; Murbraech K; Miyazaki S; Shirazi M; Santoro C; Cho GY; Popescu BA; Kosmala W; Costello B; la Gerche A; Mottram P; Thomas L; Seldrum S; Hristova K; Bansal M; Kurosawa K; Fukuda N; Yamada H; Izumo M; Tajiri K; Sinski M; Vinereanu D; Shkolnik E; Banchs J; Kutty S; Negishi K; Marwick TH
JACC Cardiovasc Imaging; 2023 Mar; 16(3):269-278. PubMed ID: 36435732
[TBL] [Abstract][Full Text] [Related]
20. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Di Persio S; Biondi-Zoccai GG
Int J Cardiol; 2009 Jun; 135(1):72-7. PubMed ID: 18572266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
